Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report

Published:January 20, 2022DOI:

      Clinical Practice Points

      • This report describes a patient with recurrent, metastatic anal squamous cell carcinoma (ASCC) who failed multiple lines of therapy followed by an impressive response to pemigatinib, an oral inhibitor of FGFR1, 2, and 3.
      • This case demonstrates how mutational analysis in the setting of advanced disease may elucidate actionable mutations when standard therapies have been exhausted.
      • Targeted FGFR inhibition may provide benefit to patients with advanced, refractory, FGFR-aberrant ASCC. Randomized trials would be helpful to better describe efficacy and durability of response.



      ASCC (Anal squamous cell carcinoma), FGFR (Fibroblast growth factor receptor)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ornitz DM
        • Itoh N.
        The Fibroblast Growth Factor signaling pathway.
        WIREs Dev Biol. 2015; 4: 215-266
        • Porta R
        • Borea R
        • Coelho A
        • et al.
        FGFR a promising druggable target in cancer: molecular biology and new drugs.
        Crit Rev Oncol Hematol. 2017; 113: 256-267
        • Helsten T
        • Elkin S
        • Arthur E
        • Tomson BN
        • Carter J
        • Kurzrock R
        The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing.
        Clin Cancer Res. 2016; 22: 259-267
        • Facchinetti F
        • Hollebecque A
        • Bahleda R
        • et al.
        Facts and new hopes on selective FGFR inhibitors in solid tumors.
        Clin Cancer Res Off J Am Assoc Cancer Res. 2020; 26: 764-774
      1. Cancer of the anus, anal canal, and anorectum - cancer stat facts. SEER. Accessed September 27, 2021.

      2. Anal cancer mortality statistics. Cancer Research UK. Published May 14, 2015. Accessed September 27, 2021.

        • Chung JH
        • Sanford E
        • Johnson A
        • et al.
        Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.
        Ann Oncol. 2016; 27: 1336-1341
        • Abou-Alfa GK
        • Sahai V
        • Hollebecque A
        • et al.
        Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
        Lancet Oncol. 2020; 21: 671-684
        • Morris VK
        • Salem ME
        • Nimeiri H
        • et al.
        Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
        Lancet Oncol. 2017; 18: 446-453
        • Marabelle A
        • Le DT
        • Ascierto PA
        • et al.
        Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
        J Clin Oncol. 2020; 38: 1-10
        • Kim HR
        • Kim DJ
        • Kang DR
        • et al.
        Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
        J Clin Oncol Off J Am Soc Clin Oncol. 2013; 31: 731-737
        • Chang J
        • Liu X
        • Wang S
        • et al.
        Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis. Härkönen PL.
        PLoS ONE. 2014; 9e105524
        • Gerlinger M
        • Rowan AJ
        • Horswell S
        • et al.
        Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing.
        N Engl J Med. 2012; 366: 883-892
        • Lanman RB
        • Mortimer SA
        • Zill OA
        • et al.
        Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
        PLoS ONE. 2015; 10e0140712
        • Walker F
        • Abramowitz L
        • Benabderrahmane D
        • et al.
        Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus.
        Hum Pathol. 2009; 40: 1517-1527
        • Palakurthi S
        • Kuraguchi M
        • Zacharek SJ
        • et al.
        The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity.
        Cancer Immunol Res. 2019; 7: 1457-1471